companies / snipr-bio
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-07 json
| total_raised | 108,000,000108.0M | ○ |
|---|---|---|
| founded | 2017 | |
| hq | Copenhagen, Denmark | |
| industry | unknown | |
| stage | series-b+ |
SNIPR Biome is a Danish clinical-stage biotech developing CRISPR-based precision medicines that selectively kill harmful bacteria, led by SNIPR001 against drug-resistant E. coli. It targets patients at risk of life-threatening infections, like transplant patients. Its edge is microbiome-targeting CRISPR that spares commensal flora.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-08-15 | series-b | 37,800,00037.8M | null | ○ |
| fact | status | src |
|---|---|---|
| Series B, $37.8M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |